Clinical Trials · NCT03962010
A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- Genexine, Inc.
- Enrollment
- 78
- Start date
- Jun 2019
- Locations
- See registry
- Primary endpoint
- Change in HbA1c